Form 4: Bio-Rad EVP James Barry Reports RSU Vesting and Stock Sale

Bio-Rad Laboratories EVP, James Barry, reported the vesting of restricted stock units, a subsequent tax-related sale of Class A common stock, and a new grant of restricted stock units.

Summary

• James Barry, EVP, President, LSG of Bio-Rad Laboratories, Inc., reported transactions involving the company's Class A common stock and restricted stock units (RSUs).
• On September 5, 2025, Mr. Barry was granted 4,110 restricted stock units.
• On September 6, 2025, 1,056 restricted stock units vested and converted into 1,056 shares of Bio-Rad Class A common stock.
• Concurrently, 378 shares of Bio-Rad Class A common stock were disposed of at a price of $295.43 per share to cover tax liabilities related to the RSU vesting.
• Following these transactions, Mr. Barry beneficially owns 1,209.555 shares of Bio-Rad Class A common stock and 3,168 restricted stock units.
• The reported transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions (RSU vesting, tax-related sale, new RSU grant) which are generally neutral in sentiment as they do not indicate new strategic direction or significant operational changes.

Positives

• The vesting of 1,056 restricted stock units resulted in the acquisition of 1,056 shares of Bio-Rad Class A common stock by the executive.
• A new grant of 4,110 restricted stock units was awarded to the executive, indicating continued incentive alignment.

Negatives

• 378 shares of Bio-Rad Class A common stock were sold to cover tax liabilities, representing a reduction in direct share ownership.

Future Outlook

The newly granted restricted stock units (4,110) are scheduled to vest over four years at 25% per year on the yearly anniversary date of the grant (September 5th).

Management Comments

• The transactions reported reflect routine insider activity, including the vesting of previously granted restricted stock units and the subsequent sale of shares to cover tax obligations.

Industry Context

This Form 4 filing is a standard disclosure of insider trading activity, common across all publicly traded companies, and does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The filing indicates routine executive compensation activity, which is a standard part of corporate governance and executive incentive structures. It does not suggest any immediate material impact on the company's operational or financial performance.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• Future vesting events for the remaining 3,168 restricted stock units will occur annually on September 5th, over the next three years, at 25% per year.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions, specifically the vesting of restricted stock units and a subsequent tax-related sale, along with a new RSU grant. These are pre-scheduled events and do not provide new fundamental information about Bio-Rad Laboratories' operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as the filing does not alter the existing investment thesis.

Keywords

Bio-Rad, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Executive Compensation, Stock Sale, BIO